Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.66 |
| ▸ | FPR2 | P25090 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 3/20 | 0.64 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899637 | 0.91 | CNR1 (0.71) | CNR1NPC1RAB9ASMN1; SMN2EPHX1 | |
| SCHEMBL4894039 | 0.88 | EPHX1 (0.68) | CNR1NPC1RAB9ASMN1; SMN2EPHX1 | |
| SCHEMBL4606056 | 0.87 | EPHX1 (0.81) | CNR1NPC1RAB9ASMN1; SMN2EPHX1 | |
| SCHEMBL4638306 | 0.87 | CNR1 (0.74) | CNR1NPC1RAB9ASMN1; SMN2FPR2 | |
| SCHEMBL10192078 | 0.86 | ALDH1A1 (0.83) | CNR1NPC1RAB9ASMN1; SMN2EPHX1 | |
| SCHEMBL2056389 | 0.85 | KDM4E (0.72) | CNR1RAB9ASMN1; SMN2FPR2ROCK2 | |
| SCHEMBL4637328 | 0.85 | CNR1 (0.77) | CNR1NPC1RAB9ASMN1; SMN2EPHX1 | |
| SCHEMBL13185536 | 0.84 | POLB (0.70) | NPC1RAB9ASMN1; SMN2CA2ROCK2 | |
| SCHEMBL4639023 | 0.84 | CNR1 (0.75) | CNR1NPC1RAB9ASMN1; SMN2EPHX1 | |
| SCHEMBL4894746 | 0.83 | CNR1 (1.00) | CNR1NPC1RAB9ASMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807390-A4 | ARYLALKYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORP (US) | 2008-07-02 | — | — | EP | claimed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | claimed |
| EP-1807390-A2 | ARYLALKYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2007-07-18 | — | — | EP | claimed |
| WO-2006052542-A2 | ARYLALKYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-05-18 | — | — | WO | claimed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | CNR1, CNR2, GPR119 | CNR1 1/4885NPC1 511/4885RAB9A 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.